Indium (In111) Oxinat Curiumpharma

Indium-111 oxine, the active ingredient in Indium (In111) Oxinat Curiumpharma, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed to label leukocytes, enabling scintigraphic detection of infection and inflammation in patients. GNH USA supplies Indium (In111) Oxinat Curiumpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Indium (In111) Oxinat is used in nuclear medicine to visualize infection‑related processes through leukocyte labeling. - Leukocyte scintigraphy for detection of infection: provides whole‑body imaging of bacterial or fungal foci by tracking radiolabelled white blood cells. - Inflammation imaging: highlights areas of active inflammation in soft tissue, bone, or vascular structures. - Evaluation of prosthetic joint infection: helps differentiate septic from aseptic loosening of joint implants.

Adverse reactions are generally related to the radiopharmaceutical nature of the product and the injection procedure.

Common Side Effects: - Transient flushing or warmth at the injection site - Mild nausea or vomiting - Headache - Injection‑site pain or bruising - Temporary mild leukopenia

Serious or Rare Side Effects: - Allergic or anaphylactic reaction - Severe radiation‑induced leukopenia or thrombocytopenia - Significant hypersensitivity with rash or bronchospasm - Unexpected organ radiation injury - Acute hemolysis (very rare)

Use of Indium (In111) Oxinat requires careful assessment of patient condition and handling of radioactive material. - Pregnancy: avoid unless the diagnostic benefit outweighs fetal radiation risk. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal impairment: evaluate radiation dose and clearance. - Concurrent radiopharmaceuticals: avoid overlapping scans that could interfere with image interpretation. - Radiation safety: follow institutional protocols for shielding, waste disposal, and personnel monitoring. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium (In111) Oxinat may interact with other agents that affect leukocyte function or radiation exposure.

Major Interactions (Avoid): - Co‑administration of other gamma‑emitting radiopharmaceuticals that overlap indium‑111 energy peaks. - High‑dose chelating agents (e.g., DTPA) that can strip indium from labelled cells. - Therapeutic steroids that markedly suppress leukocyte activity.

Moderate Interactions (Monitor Closely): - Anticoagulants may increase bleeding risk at the injection site. - Immunosuppressive drugs can reduce labeling efficiency and image quality. - Iodinated contrast agents used in CT may affect subsequent scintigraphic interpretation. - Beta‑blocking agents may alter peripheral blood flow, influencing cell distribution. - High‑dose vitamin C supplements could theoretically affect oxidative stability of the radiolabel.